Related Experiment Video
Updated: Jan 13, 2026
Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
Published on: July 28, 2023
Comparison of Vonoprazan and Low-Dose Amoxicillin Dual Therapy with Bismuth-Containing Quadruple Therapy for Naïve
Xue Fan1, Yanyan Shi2, Yuan Li1
1Department of Gastroenterology, Peking University International Hospital, Beijing 102206, China.
Objective:
This study aimed to compare the effectiveness and safety of vonoprazan-amoxicillin (VA) dual therapy with modified bismuth-containing quadruple therapy (esomeprazole, bismuth, amoxicillin, and clarithromycin; EBAC) in treatment-naïve patients infected with Helicobacter pylori (H. pylori).
Methods:
In this single-center, open-label, randomized controlled trial conducted from July to December 2024, a total of 504 H. pylori-positive patients were randomly allocated to receive either VA (vonoprazan 20 mg and amoxicillin 1000 mg, twice daily for 14 days) or EBAC (esomeprazole 20 mg bid, bismuth potassium citrate 220 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, twice daily for 14 days). The primary endpoint was the H. pylori eradication rate, and the secondary endpoint was safety.
Results:
In the intention-to-treat (ITT) analysis, the eradication rates were 79.4% (200/252) in the VA group and 85.7% (216/252) in the EBAC group (p = 0.060). Per-protocol (PP) analysis showed comparable eradication rates between the two groups (92.1% [197/214] vs. 93.0% [213/229], p = 0.712), confirming the non-inferiority of VA compared to EBAC. The incidence of adverse events was significantly fewer in the VA group (27.2% vs. 42.7%, p < 0.001). Logistic regression identified medication adherence (≥80%) as the only independent predictor of successful eradication (OR 17.557, p < 0.001).
Conclusions:
VA dual therapy achieved comparable H. pylori eradication rates to EBAC, while offering better safety and a more convenient regimen, supporting it as a preferred first-line treatment for H. pylori infection.
More Related Videos
05:23Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
04:56Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
Published on: May 16, 2025
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...